Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04303195 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis

A Phase 2 study of Diabetic Gastroparesis and Idiopathic Gastroparesis, sponsored by Neurogastrx.

Completed
Registry status
Phase 2
Development phase
161
Enrollment target
20
Study locations

NCT04303195 is a Phase 2 study of Diabetic Gastroparesis and Idiopathic Gastroparesis that has completed, run by Neurogastrx. The registered enrollment target is 161 participants, above the 138-participant average among 7 other Diabetic Gastroparesis trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04303195, a Phase 2 study of Diabetic Gastroparesis and Idiopathic Gastroparesis, has completed, sponsored by Neurogastrx.

COMPLETED
Registry status
Phase 2
Development phase
161 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.

Conditions Studied

Diabetic Gastroparesis Idiopathic Gastroparesis

Interventions

  • DRUG Placebo
  • DRUG NG101

Study Locations (20)

California

  • GW Research, Inc - Chula Vista
  • Precision Research Institute, LLC - Chula Vista
  • Kindred Medical Institute for Clinical Trials, LLC - Corona
  • Diagnamics Inc. - Encinitas
  • Paragon Rx Clinical, Inc - Garden Grove
  • United Clinical Research - Irvine
  • Prime Care Clinical Rsearch - Laguna Hills
  • Torrance Clinical Research Institute, Inc. - Lomita
  • Angel City Research - Los Angeles
  • United Clinical Research - Murrieta
  • Diabetes Medical Center of California - Northridge
  • Precision Research Institute - San Diego

Alabama

  • Digestive Health Specialists - Dothan
  • G & L Research, LLC - Foley
  • East View Medical Research - Mobile

Arizona

  • Phoenix Medical Group - Peoria
  • Phoenix Clinical LLC - Phoenix
  • Del Sol Research Management - Tucson

Arkansas

  • Preferred Research Partners - Little Rock

Colorado

  • Peak Gastroenterology Associates - Colorado Springs

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2020-08-01
Est. Completion 2023-02-25
Phase Phase 2

Sponsor

Neurogastrx

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04303195

The ClinicalTrials.gov registry entry for NCT04303195 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 138-participant average among 7 other Diabetic Gastroparesis trials with a reported enrollment target (17% higher). The listed sponsor is Neurogastrx, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Diabetic Gastroparesis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04303195 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT04303195 about?

NCT04303195 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis". The purpose of this study is to assess the safety and efficacy of various dose levels of NG101 compared with placebo in adult participants with gastroparesis during 12 weeks of treatment.

What is the current status of trial NCT04303195?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 161 participants. The study started on 2020-08-01. Estimated completion is 2023-02-25.

What conditions does trial NCT04303195 study?

This clinical trial studies the following conditions: Diabetic Gastroparesis, Idiopathic Gastroparesis.

What interventions are being tested in trial NCT04303195?

The interventions under investigation include: Placebo (DRUG), NG101 (DRUG).

Who is sponsoring clinical trial NCT04303195?

This trial is sponsored by Neurogastrx, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04303195 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetic Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diabetic Gastroparesis

All registered trials for this condition

Idiopathic Gastroparesis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.